Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "MPD, MDS and Other Blood Disorders" returned 25 results:


A Phase 2 Pilot Trial of Ruxolitinib combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
Principal Investigator(s): John Mascarenhas

Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
Principal Investigator(s): Keren Osman

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis – A phase II study
Principal Investigator(s): John O. Mascarenhas

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Principal Investigator(s): Dr. John Mascarenhas

Filgrastim-Mobilized Blood Stem Cells for Transplantation
Principal Investigator(s): Luis M. Isola

An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
Principal Investigator(s): John O. Mascarenhas

Combination Therapy of Ruxolitinib and Decitabine in patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase Disease
Principal Investigator(s): John Mascarenhas

A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIES
Principal Investigator(s): Dr. Randall Holcombe

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Principal Investigator(s): Shyamala Navada

Phase I/II Study of Combination oral JAK2 tyrosine kinase inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) therapy in patients with Myelofibrosis
Principal Investigator(s): John O. Mascarenhas

A Phase III, International, Randomized, Controlled Study of Rigosertib versus
Principal Investigator(s): Dr. Lewis Silverman

Ruxolitinib in Combination with High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis
Principal Investigator(s): Dr. Marina Kremyanskaya

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
Principal Investigator(s): Ronald Hoffman

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission. (CC-486-AML-001)
Principal Investigator(s): Lewis Silverman

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Principal Investigator(s): Luis M. Isola

A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose
Principal Investigator(s): Dr. John Mascarenhas

Open label study of single agent oral RG7388 in patients with polycythemia vera and essential thrombocythemia, with pilot feasibility study in combination with pegylated interferon alfa 2a
Principal Investigator(s): Dr. John Mascarenhas

MPD-RC 111: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk PV or High Risk ET who are Either Hydroxurea Resistent or Intolerant or Have Had Abdominal Vein Thrombosis
Principal Investigator(s): Ronald Hoffman

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Principal Investigator(s): Dr. Lewis Silverman

A Phase 3, Multicenter, Randomized, Double- Blind Study To Compare The Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects With Red Blood Cell Transfusion-Dependent Anemia And Thrombocytopenia Due To IPSS Lower-Risk Myelodysplastic Syndromes
Principal Investigator(s): Lewis Silverman

PHASE I, OPEN LABEL, STUDY OF PGV001 A MULTI-PEPTIDE THERAPEUTIC VACCINE PLATFORM FOR THE TREATMENT OF SOLID TUMORS IN THE ADJUVANT SETTING
Principal Investigator(s): Dr. Nina Bhardwaj

A Phase 2, Open-Label, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF)
Principal Investigator(s): John Mascarenhas

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Principal Investigator(s): Dr. Lewis Silverman